Vera Therapeutics, Inc. VERA · Stock Open Vera Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Vera Therapeutics, Inc. Analysis (VERA)
Is Vera Therapeutics, Inc. a good investment? Vera Therapeutics, Inc. (VERA) is currently trading at 27.99 USD. Market analysts have a consensus price target of 74.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: Vera Therapeutics, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -4.25.
Investor FAQ
Does Vera Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Vera Therapeutics, Inc.?
Vera Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -5.87.
Company Profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Community Discussion